TaiGen Biotechnology Company, Ltd

[On Demand]
TaiGen focuses in the research and development of NCEs. TaiGen’s pipeline includes best-in-class treatment for infectious diseases and antivirals.
- Taigexyn® is the first to market asset and approved by the Taiwan FDA & China NMPA. With the launch of Taigexyn® in 2016, TaiGen reached another milestone in its history and Taigexyn has been partnered in other 33 countries, including Canada, Australia, New Zealand, CIS and LATAM.
TG-1000, a novel small molecular, pan-influenza antiviral, demonstrates better activity than Xofluza (Baloxavir). It inhibits the viral cap-dependent endonuclease and effectively halts virus replication and spread.
- TG-1000 is effective against type A and B influenza, avian influenza H7N7, as well as Tamiflu-resistant viruses. Ph1 has been completed in China, and Ph2 expects to be completed in Q3-Q4 2021.

TaiGen Biopharmaceutical Holdings Limited, the holding company of TaiGen, is listed company on the Taipei Exchange.
Taipei Exchange
Company Type:
Publicly Traded Company
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Taigexyn (Nemonoxacin), TG-1000
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Director, Medicinal Chemisty
TaiGen Biotechnology Co., Ltd.